Indivior Has Some Explaining To Do At R&D Day After Nasal Naloxone Spray Fails To Get FDA OK

News that Indivior PLC's nasal naloxone spray has failed to get FDA approval is a painful setback for the addiction company given that it has already seen two other products delayed this year - and should make the recently spun-off group's Dec. 9 R&D day in New York City that much more interesting.